Please Wait...

Arthritis

Clinical Assessment of Rheumatoid Arthritis: Advantage MRI

  • 0
  • 29 Aug

When designing imaging endpoints for prospective clinical trials in Rheumatoid Arthritis (RA), sponsors often consider the use of Magnetic Resonance Imaging (MRI) for assessment. The utilization of MRI enables the detection of soft tissues for synovial and bone marrow findings in addition to structural damage, providing advanced evaluation of RA.

Read More
Anti Nerve Growth Factor

Monitoring the Joint Safety of Anti-Nerve Growth Factor Drugs

  • 0
  • 25 Jul

The March 12, 2012 meeting of the Arthritis Advisory Committee (AAC) of the Food and Drug Administration (FDA) focused on the safety of the anti-nerve growth factor (anti-NGF) drug class. Anti-NGF agents are being developed primarily for the treatment of chronic pain associated with osteoarthritis (OA).

There are three anti-nerve growth factor monoclonal antibodies in clinical development including:

  • Tanezumab (Pfizer) in phase III
  • Fulranumab (Janssen) in phase II
  • REGN475 (Regeneron) in phase II
Read More

MRI in Rheumatoid Arthritis Clinical Trials

  • 0
  • 13 Jan

At BioClinica we are fortunate to have a medical affairs group staffed with a medically and scientifically qualified team whose role is to help sponsors with imaging protocol design and how to use emerging technologies to our advantage. Harris Ahmad, M.D.

Read More

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

What's next from Bioclinica? Hear if first during #PCTrials Europe next week in Amsterdam! https://t.co/ICngaxA9mg https://t.co/SXxPj3NpD2
bioclinica (5 hours ago)
Join Bioclinica's Justin Hunt on Nov. 28 in a live webinar! Find out how to overcome common hurdles in CTMS impleme… https://t.co/wHfWHtI7sj
bioclinica (Yesterday)
Another CRO seeing big gains in the sites payments process! Access the Case Study here https://t.co/jsCxhmKcLo https://t.co/LpIKEtBKtE
bioclinica (Yesterday)
Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a… https://t.co/8ymd2Q9KcJ
bioclinica (Yesterday)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv… https://t.co/MpxTDV1T1L
bioclinica (Yesterday)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices